Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
A Cross-Country Analysis of the Determinants of COVID-19 Fatalities
Toya et al., SSRN (Preprint)
Toya et al., A Cross-Country Analysis of the Determinants of COVID-19 Fatalities, SSRN (Preprint)
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Country based analysis finding lower mortality with the use of HCQ.
Toya et al., 23 Apr 2021, preprint, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: re v ie we d 9028 2021 April 2021 A Cross-Country Analysis of the Determinants of Covid-19 Fatalities Pr ep r int no tp ee r Hideki Toya, Mark Skidmore This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3832483 er re vie we d Impressum: Pr ep rin tn ot pe CESifo Working Papers ISSN 2364-1428 (electronic version) Publisher and distributor: Munich Society for the Promotion of Economic Research - CESifo GmbH The international platform of Ludwigs-Maximilians University’s Center for Economic Studies and the ifo Institute Poschingerstr. 5, 81679 Munich, Germany Telephone +49 (0)89 2180-2740, Telefax +49 (0)89 2180-17845, email office@cesifo.de Editor: Clemens Fuest https://www.cesifo.org/en/wp An electronic version of the paper may be · from the SSRN website: www.SSRN.com · from the RePEc website: www.RePEc.org · from the CESifo website: https://www.cesifo.org/en/wp This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3832483 iew ed CESifo Working Paper No. 9028 pe er re v A Cross-Country Analysis of the Determinants of Covid-19 Fatalities Abstract Over the last year the world experienced the COVID-19 pandemic coupled with unprecedented policy responses. In this paper we examine the determinants of COVID-19 infections and fatalities in a cross-country analysis. We find that countries with greater income, less dense and greater elderly populations, fewer hospital beds, and more freedom experienced greater fatalities, and that travel restrictions and use of hydroxychloroquine reduced deaths. However, we find little evidence that lockdowns reduced fatalities, and though use of PCR testing resulted in more recorded infections, it was unassociated with fatalities. JEL-Codes: O100, O200, Q540. ot Keywords: pandemic, Covid-19, fatalities. Mark Skidmore Michigan State University 67 Morrill Hall of Agriculture USA – East Lansing, MI 48824-1039 mskidmor@msu.edu ep rin tn Hideki Toya Faculty of Economics Nagoya City University Yamanohata-1, Mizuho-cho, Mizuho-ku Japan – Nagoya, 467-8501 toya@econ.nagoya-cu.ac.jp Pr No organizations provided funding for this research. This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3832483 iew ed
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit